PMID- 21063156
OWN - NLM
STAT- MEDLINE
DCOM- 20110224
LR  - 20161125
IS  - 1883-0498 (Electronic)
IS  - 0023-2513 (Linking)
VI  - 56
IP  - 3
DP  - 2010 Sep 30
TI  - Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid 
      arthritis, treated with non-biological disease modifying anti-rheumatic drugs.
PG  - E98-107
AB  - BACKGROUND: Rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), 
      C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) have been 
      studied extensively as prognostic markers of rheumatoid arthritis (RA). However, 
      despite the fact that matrix metalloproteinase-3 (MMP-3) is linked to RA 
      activity, few studies have evaluated MMP-3 as prognostic marker. OBJECTIVE: To 
      evaluate the performance of MMP-3 as predictor of joint destruction in RA treated 
      with non-biological disease modifying anti-rheumatic drugs. METHODS: In a 
      retrospective study of 58 early to moderate stage RA patients who consulted the 
      Department of Clinical Pathology and Immunology, Kobe University Hospital between 
      May 2002 and April 2009, we evaluated the performance of MMP-3 and other 
      biomarkers as predictors of joint destruction, by comparing them between 
      radiographically progressive and non-progressive group. RESULTS: Serum levels of 
      RF at entry and ACPA, but not MMP-3 at entry, were significantly higher for the 
      progressive group. Ratios of patients with MMP-3 levels higher than healthy 
      control were not significantly different for the two groups. However, cutoff 
      values determined through receiver operating characteristic analysis showed that 
      the ratio of patients with elevated RF was significantly higher in the 
      progressive group (p=0.001), while MMP-3 (p=0.092), ACPA (p=0.052), CRP 
      (p=0.056), and ESR (p=0.069) tended to be more elevated in the progressive group. 
      Multiple logistic regression analysis using the cutoff value identified MMP-3 
      positive and RF positive, but not ACPA, CRP or ESR, as significant factors for 
      radiographic progression (OR 16.79 [95% CI: 1.34-414.19]). CONCLUSION: MMP-3 can 
      be a useful marker for prediction of joint destruction.
FAU - Mamehara, Akira
AU  - Mamehara A
AD  - Department of Clinical Pathology and Immunology, Kobe University Graduate School 
      of Medicine, Kobe, Japan.
FAU - Sugimoto, Takeshi
AU  - Sugimoto T
FAU - Sugiyama, Daisuke
AU  - Sugiyama D
FAU - Morinobu, Sahoko
AU  - Morinobu S
FAU - Tsuji, Goh
AU  - Tsuji G
FAU - Kawano, Seiji
AU  - Kawano S
FAU - Morinobu, Akio
AU  - Morinobu A
FAU - Kumagai, Shunichi
AU  - Kumagai S
LA  - eng
PT  - Journal Article
DEP - 20100930
PL  - Japan
TA  - Kobe J Med Sci
JT  - The Kobe journal of medical sciences
JID - 0413531
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - *Arthritis, Rheumatoid/blood/diagnostic imaging/drug therapy
MH  - *Arthrography
MH  - Biomarkers/*blood
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Joints
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2010/11/11 06:00
MHDA- 2011/02/25 06:00
CRDT- 2010/11/11 06:00
PHST- 2010/11/11 06:00 [entrez]
PHST- 2010/11/11 06:00 [pubmed]
PHST- 2011/02/25 06:00 [medline]
PST - epublish
SO  - Kobe J Med Sci. 2010 Sep 30;56(3):E98-107.